Press Center
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.
Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients
Priothera is working to initiate the MO-TRANS global Phase IIb/III study in Europe, US and Japan
Priothera Receives FDA clearance of Investigational New Drug (IND)
Global Phase IIb/III trial (MO-TRANS) assessing the efficacy and safety of mocravimod…
Priothera to present an abstract at the TANDEM Meetings / Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR – April 23-26 2022
The success of allogeneic hematopoietic stem cell transplantation (HSCT)…
Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Global Phase IIb/III trial assessing the efficacy and safety of mocravimod…
Priothera Receives R&D Innovation Loan from Bpifrance
€1.5 million loan will further support clinical manufacture of mocravimod…
Priothera presents at EBMT conference March 20-23
Priothera presents at EBMT conference March 20-23
No results found.